Status:
COMPLETED
Paclitaxel-HDFL for Locally Advanced and Recurrent/Metastatic Gastric Cancers
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Locally Advanced and Recurrent/Metastatic Gastric Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy,response rate,time to treatment failure,overall survival,toxicities of Paclitaxel-HDFL regimen in locally advanced/inoperable and recurrent/metast...
Detailed Description
In the treatment of metastatic breast cancer, paclitaxel followed by weekly HDFL has been shown to have a 55% response rate in anthracycline-resistant patient. Recently, regimen combining paclitaxel a...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed gastric adenocarcinoma 2.Measurable or evaluable disease 3.No previous C/T 4.Age 18 \~ 70 years 5.KPS \>=60% 6.WBC\>=4,000, pltate\>=100K, Creatinine\<=1.5mg/dl, serum bil\<=1x UNL, transaminase\<=3.5x ULN
Exclusion
- CNS metastasis 2.Patients receive concomitant anti-cancer C/T or R/T 3.Patients who are pregnant and with an expected life expectancy less than 3months 4.Symptomatic heart disease,active infection, extensive liver disease or liver cirrhosis 5.TG\<=70mg/dl 6.Mental status is not fit for clinical trial
- \-
Key Trial Info
Start Date :
April 1 1997
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00154726
Start Date
April 1 1997
End Date
August 1 2005
Last Update
November 22 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.